Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Acrivon Therapeutics, Inc. Common Stock

ACRV

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Last trade $1.48
Day change +$0.02 (+1.37%)
Day range $1.38 – $1.55
Volume 310,463
Market cap $63M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$62.57M
Price / earnings
—
Price / book
0.72×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.28×

Profitability

Earnings per share
-$1.73
Return on assets
-74.91%
Return on equity
-85.65%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.99×
Quick ratio
7.99×
Cash ratio
3.62×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$64.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ACRV, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.82M$4.74M$5.37M$6.04M$6.47M$6.25M$6.32M$6.28M
Research and development$13.84M$15.17M$14.75M$13.65M$16.18M$15.41M$18.63M$18.86M
Total operating expenses$18.67M$19.9M$20.12M$19.69M$22.65M$21.66M$24.95M$25.14M
Operating income-$18.67M-$19.9M-$20.12M-$19.69M-$22.65M-$21.66M-$24.95M-$25.14M
Interest expense$0$989K$0$0$0$2M$0$0
Income before taxes-$17.96M-$19.04M-$18.99M-$18.23M-$21.01M-$19.68M-$22.83M-$22.44M
Income taxes$0$0$0$0$0$0$0$0
Net income-$17.96M-$19.04M-$18.99M-$18.23M-$21.01M-$19.68M-$22.83M-$22.44M
Net income attributable to common shareholders-$17.96M-$19.04M-$18.99M-$18.23M-$21.01M-$19.68M-$22.83M-$22.44M
EBITDA-$18.26M-$19.52M-$19.76M-$19.34M-$22.31M-$21.35M-$24.65M-$24.89M
Basic earnings per share-$0.43-$0.49-$0.49-$0.47-$0.55-$0.51-$0.60-$0.59
Diluted earnings per share-$0.43-$0.49-$0.49-$0.47-$0.55-$0.51-$0.60-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Acrivon Therapeutics acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a PKCθ inhibitor preclinical program from Aqilion AB for undisclosed cash consideration. The acquisition establishes immunology and inflammation as a strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first indication. Acrivon's AP3 platform profiling characterized ACR-525 as a highly selective, potentially best-in-class JAK1 inhibitor with broad potential in IBD and other autoimmune disorders.

GlobeNewswire Inc.

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics announced preclinical data showing strong synergies between its lead assets ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) when combined with anti-PD-L1 checkpoint inhibitors and ADC payloads. The company will present three posters at the AACR 2026 Annual Meeting in San Diego, demonstrating potent efficacy and durable immune memory in combination therapies, supporting potential frontline clinical development opportunities.

GlobeNewswire Inc.

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics announced three poster presentations at the 2026 AACR Annual Meeting showcasing preclinical data demonstrating strong synergy of ACR-368 (CHK1/2 inhibitor) with Topoisomerase 1 inhibitor ADC payloads, and synergy of both ACR-368 and ACR-2316 (WEE1/PKMYT1 inhibitor) with immune checkpoint inhibitors. The data highlight the company's AP3 platform's ability to identify therapeutic candidates and combinations with clinical potential.

GlobeNewswire Inc.

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.